The correlation between diabetes mellitus type ii and the increased risk of alzheimer’s disease: a collaborative treatment approach

Diabetes Mellitus type II is among the most common and debilitating diseases in the United States. Each year, the incidence of diabetes in the U.S. is 1.4 million [1]. It is estimated that by the year 2050, if current trends persists that one-third of American adult population will be diagnosed with diabetes [1]. Statistics have indicated that Alzheimer’s disease affects approximately one-ninth (11%) of older Americans, ages 65 and older [2]. It is further established that there will be a steady annual increase in the incidence and prevalence of AD, as older Americans continue to live longer than 65 years [4]. This paper supports the literature that links diabetes with Alzheimer’s disease. It recognizes that the coexisting complications of diabetes mellitus type II is both pervasive and disheartening. Nonetheless, we have identified both physiological and pharmacological factors that are relevant to the treatment of this epidemic. In addition, we contend that further research is needed to prevent and effectively treat both diseases. An expected outcome is that sustained circumvention of the negative side effects could lead to enhanced quality of life. We conclude that based on gender and racial disparities, the most at risk populations must be identified and targeted by healthcare educators and public health officials [3]. One implication is that responsible intervention will require a collaborative approach, which combines lifestyle changes and conventional medical approaches. This can result in improved clinical outcomes, patient longevity, and overall enhanced quality of life.